UNASSIGNED: Firstly, we developed a niosomal drug delivery system based on ceramide IIIB to form Cerosomes. Cerosomes were prepared from a mixture of Ceramide, hyaluronic acid, and edge activator using a thin-film hydration technique. To co-deliver CsA and DTH topically for the treatment of psoriasis. These two hydrophobic drugs encapsulated into our synthesized positively charged particle cerosomes.
UNASSIGNED: Cerosomes had an average particle size of (222.36 nm± 0.36), polydispersity index of (0.415±0.04), Entrapment Efficiency of (96.91%± 0.56), and zeta potential of (29.36±0.38mV) for selected formula. In vitro, In silico, in vivo, permeation, and histopathology experiments have shown that cerosomes enhanced the skin penetration of both hydrophobic drugs by 66.7% compared to the CsA/DTH solution. Imiquimod (IMQ) induced psoriatic mice model was topically treated with our CsA/DTH cerosomes. We found that our formulation enhances the skin penetration of both drugs and reduces psoriasis area and severity index (PASI score) by 2.73 times and 42.85%, respectively, compared to the CsA/DTH solution. Moreover, it reduces the levels of proinflammatory cytokines, TNF-α, IL-10, and IL-6 compared to CsA/DTH solution administration.
UNASSIGNED: The Cerosomes nano-vesicle-containing CsA/DTH represents a more promising topical treatment for psoriasis, giving new hope to individuals with psoriasis, compared to commercial and other conventional alternatives.
■首先,我们开发了一种基于神经酰胺IIIB的脂质体给药系统以形成Cerosome.Cerosome由神经酰胺的混合物制备,透明质酸,和边缘活化剂使用薄膜水化技术。共同局部递送CsA和DTH用于治疗银屑病。这两种疏水性药物包封到我们合成的带正电荷的颗粒cerosome中。
■Cerosome的平均粒径为(222.36nm±0.36),多分散指数为(0.415±0.04),捕获效率(96.91%±0.56),所选配方的zeta电位为(29.36±0.38mV)。体外,在硅片中,在体内,渗透,和组织病理学实验表明,与CsA/DTH溶液相比,cerosome将两种疏水性药物的皮肤渗透增强了66.7%。用我们的CsA/DTHcerosome局部处理咪喹莫特(IMQ)诱导的银屑病小鼠模型。我们发现我们的配方可增强两种药物的皮肤渗透,并将牛皮癣面积和严重程度指数(PASI评分)降低2.73倍和42.85%,分别,与CsA/DTH解决方案相比。此外,它降低了促炎细胞因子的水平,TNF-α,IL-10和IL-6与CsA/DTH溶液施用相比。
含Cerosomes纳米囊泡的CsA/DTH代表了一种更有希望的牛皮癣局部治疗方法,给牛皮癣患者带来新的希望,与商业和其他常规替代品相比。